- With these latest studies, the firmly established European
market leader in stroke AI imaging adds to its growing body of
evidence.
- The latest research reflects the company's extensive academic
collaborations and its growing Life Science partnerships.
OXFORD, England and
CHICAGO, May 16, 2024 /PRNewswire/ -- Brainomix, a pioneer
in artificial intelligence (AI) imaging solutions to enable
precision medicine, announced a series of new studies that were
presented this week at the European Stroke Organisation Conference
(ESOC) in Basel. The studies
validated the impact of the Oxford-based company's Brainomix 360 Stroke
platform, including its FDA-cleared Triage Stroke tool and its
flagship e-ASPECTS software.
The studies follow Wednesday's presentation at ESOC of a
groundbreaking study, the largest prospective evaluation of stroke
AI imaging, involving more than 80,000 patients at 26 sites over a
3-year period. This study showed that the implementation of
Brainomix 360 Stroke was associated with an additional 50% increase
in the number of patients receiving mechanical thrombectomy and a
reduction in door-in-door-out (DIDO) time of around 50 minutes.
Dr Michalis Papadakis, CEO
and Co-Founder of Brainomix, said: "The studies presented this week
at ESOC reflect our ongoing commitment to scientific excellence and
our extensive academic collaborations with world-class research
institutions, including the Mayo Clinic, the Rockefeller Institute
at West Virginia University, and Boston
Medical Center. These studies provide further validation that our
AI-enabled technology can play a critical role in stroke care,
helping clinicians make more confident decisions leading to more
patients getting access to life-saving treatments.
"We are also proud to showcase the growing body of research we
are conducting with Life Science partners. Our unique set of
imaging biomarkers and clinical trial tools, along with our
world-class core lab team, are delivering real value for pharma
partners, device manufacturers and biotech companies, generating
insights that may guide future clinical trial design."
Key abstracts accepted and presented at ESOC included:
- "Large Vessel Occlusion Detection in Acute Ischemic Stroke
Using Non-Contrast CT" was a multisite collaboration with the Mayo
Clinic, the Rockefeller Neuroscience Institute at West Virginia University, and Boston Medical Center
validating Triage Stroke as a reliable tool for large vessel
occlusion (LVO) detection. The authors concluded that when coupled
with clinical information such as NIHSS, the tool may help centers
to identify thrombectomy candidates, especially those with
constrained resources and basic imaging.
- Brainomix and CSL Behring jointly published a
retrospective observational study, "Automatically Quantified
Follow-Up Imaging Biomarkers as Predictors of Clinical Outcomes
after Acute Ischemic Stroke: A Real-World Evidence Study."
After processing NCCT follow-up images with Brainomix 360
Stroke software, the results validated the prognostic significance
of automated final infarct volume (FIV) and its components,
confirming the opportunity for AI-derived imaging biomarkers at
follow-up time points to improve the design and delivery of
randomized controlled trials in AIS.
- Brainomix and Acticor jointly published a poster,
"Patients Randomized to Glenzocimab Suffered Less
Hemorrhagic Transformation with Greater Benefit in Larger
Baseline Infarct Core," which helped to elucidate the mechanism and
demonstrate the efficacy of Acticor's drug, glenzocimab, while
identifying subgroups of patients who appear to benefit the
most.
- A UK study, "WOW (With Or Without): Measuring Impact of
e-ASPECTS Software on Conventional CT Reporting in Acute
Ischemic Stroke," validated the impact of e-ASPECTS on
reader performance. "e-ASPECTS is a valuable tool for
clinicians in the speedy and accurate diagnosis of acute
ischemic stroke (AIS), and has the potential to enable the
identification of AIS patients in centres without
neuroradiology expertise, improving access to life-saving
treatment," noted Dr Anna Podlasek,
lead author of the study.
- RESILIENT Extend IV, an ongoing randomized controlled trial
assessing Tenecteplase in non-LVO AIS patients in the
extended time window, will provide an update on its progress. The
Brazilian trial is using Brainomix 360 e-CTP for patient
selection.
About Brainomix
Brainomix specializes in the creation of AI-powered software
solutions to enable precision medicine for better treatment
decisions in stroke and lung fibrosis. With origins as a spin-out
from the University of Oxford, Brainomix is an expanding
commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries.
A private company, backed by leading healthtech investors,
Brainomix has innovated award-winning imaging biomarkers and
software solutions that have been clinically adopted in hundreds of
hospitals worldwide. Its first product, the Brainomix 360 stroke
platform, provides clinicians with the most comprehensive stroke
imaging solution, driving increased treatment rates and improving
functional independence for patients.
To learn more about Brainomix and its technology
visit www.brainomix.com, and follow us
on Twitter, LinkedIn and Facebook.
Contacts
Jeff Wyrtzen, Chief Marketing
& Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730
Media enquiries
Charles Consultants
Sue Charles
Sue@charles-consultants.com
M +44 (0)7968 726585
Logo -
https://mma.prnewswire.com/media/1989193/3856380/Brainomix_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/brainomix-announces-new-studies-further-validating-the-impact-of-brainomix-360-stroke-platform-302147720.html